Search results for "Breast Disease"

showing 10 items of 40 documents

Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.

2009

BACKGROUND: Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is a relatively new disease. The aim of this study was to evaluate the prevalence of BP-ONJ in breast cancer patients with osseous metastasis and bisphosphonate therapy. METHODS: A retrospective study was conducted in a EUSOMA accredited breast unit in Germany. All patients treated from January of 2000 to March of 2006 with metastatic breast cancer and bisphosphonate therapy were reviewed. All patients were contacted, and missing data were completed through structured interviews with their dentists and physicians (n = 75). Primary outcome was the development of BP-ONJ and the detection of possible additional trigger fa…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOral Surgical ProceduresBone NeoplasmsBreast NeoplasmsBreast cancerInternal medicineMedicineHumansAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)IncidenceOsteonecrosisBone metastasisCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurgeryOncologyBreast diseasebusinessJaw DiseasesCancer
researchProduct

Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR ima…

2011

To intraindividually compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast material-enhanced breast magnetic resonance (MR) imaging by using a prospective, multicenter double-blind, randomized protocol.Institutional review board approval and patient informed consent were obtained. One hundred sixty-two women (mean age, 52.8 years ± 12.3 [standard deviation]) enrolled at 17 sites in Europe and China between July 2007 and May 2009 underwent at least one breast MR imaging examination at 1.5 T by using three-dimensional spoiled gradient-echo sequences. Of these, 151 women received both contrast agents in randomized order in otherwise identical examinatio…

AdultGadolinium DTPAChinaContrast MediaBreast NeoplasmsSensitivity and Specificitylaw.inventionDouble blindbreast neoplasm contrast media MRIBreast cancerMegluminebreast neoplasmRandomized controlled trialDouble-Blind MethodlawPredictive Value of TestsImage Interpretation Computer-AssistedmedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyGADOBENATE DIMEGLUMINEAgedAged 80 and overChi-Square DistributionCross-Over Studiesbusiness.industryMiddle Agedmedicine.diseaseMr imagingCrossover studyMagnetic Resonance ImagingEuropeFemaleBreast diseaseNuclear medicinebusinessMRIRadiology
researchProduct

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases

2008

Male breast cancer (MBC) is a rare and poorly known disease. Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC. Interestingly, BRCA2 germ-line rearrangements have been described in high-risk breast/ovarian cancer families which included at least one MBC case. Germ-line mutations of CHEK2 gene have been also implicated in inherited MBC predisposition. The CHEK2 1100delC mutation has been shown to increase the risk of breast cancer in men lacking BRCA1/BRCA2 mutations. Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate c…

AdultMaleCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1male breast cancerProtein Serine-Threonine KinasesBiologychek2medicine.disease_causeBreast Neoplasms Malebrca1Breast cancerbrca2medicineHumansBRCA1/BRCA2germ-line mutationsMultiplex ligation-dependent probe amplificationmlpaskin and connective tissue diseasesneoplasmsCHEK2Germ-Line MutationGene RearrangementMutationCancerGene rearrangementmedicine.diseaseCheckpoint Kinase 2Oncologylarge genomic rearrangementsMale breast cancerCancer researchbrca1; brca2; chek2; germ-line mutations; large genomic rearrangements; male breast cancer; mlpaBreast diseaseBreast Cancer Research and Treatment
researchProduct

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

2008

Abstract Purpose: Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention not only as a prognostic factor in breast cancer but also as a potential target for immunotherapy. We examined Ep-CAM expression in 402 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting. Experimental Design: Ep-CAM expression was evaluated by immunostaining. Its prognostic effect was estimated relative to overexpression/amplification of HER-2, histologic grade, tumor size, age, and hormone receptor expression. Results: Ep-CAM status was positive in 106 (26.4%) patients. In multivariate analysis, Ep-CAM status was associated with disea…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyNeoplasms Hormone-DependentEstrogen receptorBreast Neoplasmschemistry.chemical_compoundDrug Delivery SystemsBreast cancerAntigens NeoplasmInternal medicineProgesterone receptorBiomarkers TumormedicineHumansAgedAged 80 and overbusiness.industryHazard ratioCancerEpithelial cell adhesion moleculeMiddle AgedEpithelial Cell Adhesion MoleculePrognosismedicine.diseaseOncologychemistryHormone receptorLymphatic MetastasisFemaleBreast diseasebusinessCell Adhesion MoleculesClinical Cancer Research
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct

Long-term population-based risks of breast cancer after childhood cancer

2008

Previous studies have reported substantially increased risks of breast cancer among survivors of childhood cancer at 10–20 years posttreatment. Whether these excess risks are sustained beyond 40 years of age when general population incidence of breast cancer begins its steep increase is largely unknown. We quantified the risk of breast cancer in adult female survivors with considerably more survivors followed-up beyond 40 years of age than previously available. Standardized Incidence Ratios (SIR), Excess Absolute Risks (EAR), and cumulative incidence were calculated within a population-based cohort of 8,093 female survivors of childhood cancer. Poisson regression models were used to model S…

AdultRiskCancer Researchmedicine.medical_specialtyPopulationBreast NeoplasmsCohort StudiesBreast cancermedicineHumansCumulative incidenceSurvivorsRisk factorChildeducationAgededucation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseSurgeryOncologyRelative riskMultivariate AnalysisFemaleBreast diseasebusinessSEER ProgramDemographyInternational Journal of Cancer
researchProduct

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

2010

Background: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer. Methods: Osteopontin, ALCAM, HER2 and ER mRNA expression in breast cancer tissues of 481 patients were analysed (mRNA microarray analysis, kinetic RT–PCR). Hierarchical clustering was performed in training cohort A (N=100, adjuvant treatment) and validation cohorts B (N=200, no adjuvant treatment, low-risk) and C (N=181, adjuvant treatment, high-risk). Results: Negative/low ER and HER2, high OPN and low ALCAM mRNA expression helped to identify patients at particularly h…

AdultRiskCancer ResearchosteopontinReceptor ErbB-2Eukaryotic Initiation Factor-3discriminative markersBreast NeoplasmsDisease-Free SurvivalHER2 and ER-negative breast cancerBreast cancerActivated-Leukocyte Cell Adhesion MoleculemedicineCluster AnalysisHumansOsteopontinRNA MessengerReceptorskin and connective tissue diseasesMolecular DiagnosticsALCAMALCAMAgedOligonucleotide Array Sequence AnalysisbiologyCell adhesion moleculeDecision TreesActivated-Leukocyte Cell Adhesion MoleculeCancerMiddle Agedmedicine.diseasePrognosisOncologyReceptors EstrogenImmunologybiology.proteinCancer researchFemaleBreast diseaseBritish journal of cancer
researchProduct

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St G…

2009

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-…

AdultTime FactorsBreast NeoplasmsKaplan-Meier EstimateRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalBreast cancerBreast cancer 3Predictive Value of TestsMedicineHumansLongitudinal StudiesProspective StudiesRisk factorAgedNeoplasm StagingRetrospective StudiesAged 80 and overNeovascularization Pathologicbusiness.industryHazard ratioCancerRetrospective cohort studyHematologyGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisTreatment OutcomeOncologyAdult; Aged; Aged 80 and over; Algorithms; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Breast Neoplasms/radiotherapy; Breast Neoplasms/surgery; Disease-Free Survival; Female; Follow-Up Studies; Genes erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neovascularization Pathologic; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors Progesterone/analysis; Regression Analysis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment OutcomeMultivariate AnalysisRegression AnalysisFemaleBreast diseasebusinessRisk assessmentReceptors ProgesteroneAlgorithmAlgorithmsFollow-Up Studies
researchProduct

Tuberous Breast

2017

Background Tuberous breast (TB) is a rare congenital deformity, which may appear in different clinical forms representing various degrees of a single pathological entity. The worst cases are characterized by severe hypoplasia. Following a detailed analysis of the available relevant literature and a significant number of treated cases, in this article, the authors propose a new classification, with the aim of summarizing and simplifying a more intuitive categorization of the malformation, considering all the clinical aspects and including all types of TBs, even the minor ones, thus allowing a more immediate diagnosis and surgical planning. Methods Between September 2006 and December 2015, 78…

Adultmedicine.medical_specialtyAdolescentMammaplastyBreast surgerymedicine.medical_treatmentSettore MED/19 - Chirurgia Plasticatuberous breast030230 surgerySurgical planningFollow-Up Studielaw.inventionBreast DiseasesYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRetrospective StudielawDeformitymedicineHumanstuberous breast correctionBreastRetrospective Studiesbusiness.industryGeneral surgeryBreast Diseasebreast malformationbreast deformityRetrospective cohort studymedicine.diseasetuberous breast classificationHypoplasiaTreatment OutcomeMammaplastyBreast implantFemaleSurgeryObservational studymedicine.symptombusinessHumanFollow-Up StudiesAnnals of Plastic Surgery
researchProduct

The accuracy of sentinel lymph node biopsy in the treatment of multicentric invasive breast cancer using a subareolar injection of tracer.

2008

BACKGROUND: The aim of this study was to evaluate the feasibility and the accuracy of sentinel lymph node biopsy in multicentric breast cancer (MBC) performed by means of a subareolar (SA) injection of both 99Tc-labeled human albumin colloid and lymphazurin. METHODS: Between January 2002 and October 2007, 34 patients with MBC with clinically negative axilla underwent sentinel lymph node biopsy (SLNB) followed by total axillary node dissection (AD). Overall successful identification rate of SLN was 100%; there were no false negatives and overall accuracy rate was 100%. RESULTS: The mean number of sentinel lymph nodes (SLNs) identified was 1.8 +/- 0.88 (range = 1-4); the mean number of axilla…

Adultmedicine.medical_specialtyAxillary lymph nodesInjections IntradermalSentinel lymph nodeBreast NeoplasmsIsosulfan BlueSettore MED/08 - Anatomia PatologicaCohort StudiesBreast cancerPredictive Value of TestsBiopsymedicineRosaniline DyesHumansRadioactive TracersColoring AgentsTechnetium Tc 99m Aggregated AlbuminAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyCarcinoma Ductal BreastReproducibility of ResultsSentinel Lymph Node Biopsy Multicentric Invasive Breast CancerMiddle Agedmedicine.diseaseSurgeryAxillaCarcinoma LobularSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureSurgeryFemaleBreast diseaseRadiologyLymphRadiopharmaceuticalsbusiness
researchProduct